#BristolMyersSquibb has reported phase 3 results with a new type of drug for #idiopathicpulmonaryfibrosis that could open the door to regulatory filings.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#BristolMyersSquibb has reported phase 3 results with a new type of drug for #idiopathicpulmonaryfibrosis that could open the door to regulatory filings.
@thedailyfathom.bsky.socialBIOTECH · FDA approves heart drug Camzyos for kids as young as 12
Camzyos becomes the first drug of its kind approved for adolescents with a dangerous thickened-heart condition.
@pharmaphorum.bsky.social#BristolMyersSquibb's GPRC5D-directed #CARTtherapy, arlocabtagene autoleucel (#arlocel), has shown activity in a phase 2 trial that could underpin future filings for #bloodcancer #multiplemyeloma.